(3RB) Reckitt Benckiser - Ratings and Ratios

Reckitt Benckiser Group plc is a multinational consumer goods company with a diverse portfolio of health, hygiene, and nutrition products. The companys extensive range of brands includes Dettol, Durex, and Lysol, which are household names globally. With a presence in numerous countries, Reckitt Benckiser generates significant revenue from various geographic regions, making it a relatively stable player in the consumer staples sector.

The companys product portfolio is segmented into several categories, including germ protection, intimate wellness, over-the-counter medications, personal care, and nutrition. Brands such as Nurofen, Gaviscon, and Strepsils are prominent in the pharmaceutical and healthcare sectors, while Airborne, Movefree, and Neuriva cater to the growing demand for vitamins and supplements. Additionally, Reckitt Benckisers infant nutrition segment, featuring brands like Enfamil and Nutramigen, contributes to the companys revenue.

With a history dating back to 1819, Reckitt Benckiser has established itself as a leading player in the personal care products industry. The companys headquarters in Slough, UK, serves as the base for its global operations, which are supported by a strong online presence through its website, https://www.reckitt.com.

Analyzing the , we observe that the stocks last price is 59.36, which is above its SMA20 and SMA50, indicating a positive short-term trend. The ATR of 1.17, equivalent to 1.97%, suggests moderate volatility. Given the current price and the 52-week high and low range (63.04 and 47.08, respectively), we can infer that the stock has been trending upwards. Using the , we see that the companys Market Cap is approximately 39.8 billion EUR, with a P/E ratio of 24.08 and a forward P/E of 15.11, indicating potential for future earnings growth.

Based on the available data, a forecast for Reckitt Benckiser Group plc can be derived. Considering the companys stable presence in the consumer staples sector, its diverse portfolio, and the technical indicators, we can expect the stock to continue its upward trend. A potential target price could be around 62-65, representing a 4-6% increase from the current price. However, this forecast is contingent upon the companys ability to maintain its RoE of 27.04 and continue delivering strong earnings growth, as implied by the forward P/E ratio.